402 related articles for article (PubMed ID: 2584703)
1. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients.
Sykes M; Chester CH; Sundt TM; Romick ML; Hoyles KA; Sachs DH
J Immunol; 1989 Dec; 143(11):3503-11. PubMed ID: 2584703
[TBL] [Abstract][Full Text] [Related]
2. Effects of T cell depletion in radiation bone marrow chimeras. I. Evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD.
Sykes M; Sheard M; Sachs DH
J Immunol; 1988 Oct; 141(7):2282-8. PubMed ID: 3049804
[TBL] [Abstract][Full Text] [Related]
3. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
Sykes M; Bukhari Z; Sachs DH
Bone Marrow Transplant; 1989 Sep; 4(5):465-74. PubMed ID: 2790325
[TBL] [Abstract][Full Text] [Related]
5. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
6. Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
Sykes M; Sharabi Y; Sachs DH
Bone Marrow Transplant; 1988 Sep; 3(5):379-86. PubMed ID: 3056545
[TBL] [Abstract][Full Text] [Related]
7. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
8. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
Blazar BR; Hirsch R; Gress RE; Carroll SF; Vallera DA
J Immunol; 1991 Sep; 147(5):1492-503. PubMed ID: 1831826
[TBL] [Abstract][Full Text] [Related]
9. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts.
Colson YL; Zadach K; Nalesnik M; Ildstad ST
Transplantation; 1995 Nov; 60(9):971-80. PubMed ID: 7491703
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.
Sykes M; Eisenthal A; Sachs DH
J Immunol; 1988 May; 140(9):2903-11. PubMed ID: 2966200
[TBL] [Abstract][Full Text] [Related]
11. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
12. Alloengraftment in IL-2-treated mice.
Sykes M; Pearson DA
Bone Marrow Transplant; 1992 Aug; 10(2):157-63. PubMed ID: 1525605
[TBL] [Abstract][Full Text] [Related]
13. Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host.
Hummel S; Wilms D; Vitacolonna M; Zöller M
J Leukoc Biol; 2002 Nov; 72(5):898-912. PubMed ID: 12429711
[TBL] [Abstract][Full Text] [Related]
14. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
15. The recovery of resistance to alloengraftment following lethal irradiation and administration of T cell-depleted syngeneic bone marrow.
Chester CH; Sykes M; Sachs DH
Bone Marrow Transplant; 1989 Mar; 4(2):195-200. PubMed ID: 2650790
[TBL] [Abstract][Full Text] [Related]
16. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
17. Suppressive activity in recipients of non-T cell-depleted allogeneic bone marrow transplants: role of T cell-depleted syngeneic marrow.
Sykes M
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():30-3. PubMed ID: 2534057
[TBL] [Abstract][Full Text] [Related]
18. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
[TBL] [Abstract][Full Text] [Related]
19. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
20. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
